The current study was conducted to compare the overall survival (OS) of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in elderly patients (those aged 80 years) with muscle-invasive bladder cancer (MIBC). METHODS: Patients aged 80 years with cT2-4, N0-3, M0 transitional cell MIBC who were treated with curative RT (60-70 Gray) or CCRT were identified in the National Cancer Data Base. Univariable and multivariable frailty survival analyses, as well as 1-to-1 propensity score matching, were used to isolate the association between CCRT and OS. RESULTS: A total of 1369 patients who were treated with RT from 2004 through 2013 met eligibility criteria: 739 patients (54%) received RT alone and 630 patients (46%) received CCRT. The median age of the patients was 84 years (range, 80-90 years). The median follow-up was 21 months. The 2-year OS rate was 48%. When comparing CCRT with RT alone, the 2-year OS rate was 56% versus 42% (P<.0001), respectively. Multivariable analysis demonstrated that CCRT (hazard ratio 
INTRODUCTION
Bladder cancer is the second most common genitourinary malignancy in the United States, with 79,030 new cases and 16,870 deaths expected in 2017. 1 More specifically, patients with muscle-invasive bladder cancer (MIBC) comprise approximately 30% of those with bladder cancer. 2 MIBC predominantly affects an older patient population, with a median age at the time of diagnosis of 73 years. 3 Patients with MIBC have a poor prognosis, with 5-year overall survival (OS) rates ranging from 40% to 60%. 4, 5 In the United States, patients with MIBC most often are treated with radical cystectomy with or without neoadjuvant or adjuvant chemotherapy, but bladder-preserving concurrent chemoradiotherapy (CCRT) after maximal transurethral resection of bladder tumor (TURBT) or trimodality therapy (TMT) remains an alternative treatment with equivalent long-term disease control and OS for well-selected patients. 6, 7 Radical cystectomy may pose a significant risk for an older population of patients with MIBC with significant comorbid disease, 8 whereas radiotherapy (RT) generally is more tolerable among older and frail patients. To the best of our knowledge, there have been 2 prospective randomized controlled trials published to date demonstrating a locoregional control benefit for CCRT compared with RT alone for the treatment of patients with MIBC and the BC2001 trial demonstrated a bladder cancer-specific survival benefit with CCRT, 9 but the patients in these studies were primarily younger and not representative of the elderly population.
Using data from the US Census, analysis of the growth of 10-year age groups demonstrated that individuals aged 85 years to 94 years experienced the fastest growth between 2000 and 2010. This age group grew by 29.9%, increasing from 3.9 million to 5.1 million. 12 Simultaneously, the use of curative treatment for MIBC in the elderly population appears to be underused. [13] [14] [15] [16] Although this underuse may be due to the burden of comorbid disease preventing patients from undergoing potentially curative surgical treatment, these individuals still may be eligible for potentially curative bladderpreserving CCRT.
Elderly patients comprised a small population in the prior randomized trials, and randomization of this question specifically for this population is unlikely. Given the paucity of randomized data for this subpopulation, we used the National Cancer Data Base (NCDB) to compare the survival of elderly patients with MIBC who were treated with CCRT compared with RT alone. We hypothesized that compared with RT alone, CCRT is associated with improved OS in elderly patients with MIBC who are treated with RT, independent of comorbidity and age.
MATERIALS AND METHODS

Study Design and Patient Data Set
We performed a retrospective cohort study using the NCDB. The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. It is a clinical oncology database sourced from CoC-accredited hospital registry data that includes approximately 70% of malignant cancers diagnosed in the United States. 17 Demographics, comorbidities, tumor characteristics, and OS are recorded, as well as therapies delivered during the first course of treatment including surgery, RT, and chemotherapy. At the time of analysis, patient data were available for cases diagnosed from 2004 through 2013. This study was reviewed and found to be exempt by the Institutional Review Board of the study institution.
Patient Selection
Elderly patients (defined as those aged 80 years) with cT2-4, N0-3, M0 transitional cell MIBC who were treated with RT to curative doses (60-70 Gray [Gy] ) to the bladder were identified. Patients were excluded if they had unknown follow-up; had unknown chemotherapy; or were treated with surgery, excluding TURBT. Figure 1 depicts the Consolidated Standards of Reporting Trials (CONSORT) diagram for inclusion and exclusion criteria.
Exposure Variables of Interest
Use of CCRT was defined as receiving chemotherapy within 30 days of the initiation of RT. The chemotherapy regimen was categorized further into 3 groups based on the number of chemotherapy agents used: single agent, multiple agents, or unknown. Patient, tumor, and treatment information also was stratified into groups.
The RT dose was analyzed both as a continuous variable and as a discrete variable by separating patients into 2 groups (patients receiving 60-64.99 Gy and patients receiving 65-70 Gy). Patient age was explored as a continuous variable. Using the Charlson-Deyo comorbidity score (CDCS) variation of the Charlson comorbidity index, comorbidity information was organized into 3 groups (0, 1, and 2 comorbidities). The extent of TURBT was quantified by stratifying patients by extent of residual disease (macroscopic total resection vs residual disease). The location in which each patient received treatment was divided by US Census region. The population density of the area in which each patient resided was categorized as metropolitan, urban, and rural. Patient distance from the reporting facility was separated into the following distances in miles: 5, 5.1 to 10, 10.1 to 20, and >20. Patient county income and educational levels were categorized as quartiles based on equally proportioned ranges among all US zip codes.
Statistical Analysis
The primary endpoint was OS, defined as the time from diagnosis to death. The Kaplan-Meier method was used to estimate OS. To account for patient clustering within their treatment facility type, generalized linear mixed effects models were used to compare clinical, treatment, and sociodemographic covariates between the RT alone and CCRT groups. Similarly, univariable analysis (UVA) and multivariable analysis (MVA) frailty survival models that allowed for the clustering of patients within their treatment facility type were used to estimate the hazards of patient mortality at any given time as a function of demographics, clinical measures, and comorbidities. All covariates with a P <.10 on UVA were retained in the final MVA. The assumption of proportional hazards for each predictor was assessed as described by Lin et al. 18 Analyses were performed using STATA MP 14 (StataCorp LLC, College Station, Tex) and SPSS (IBM Corporation, Armonk, NY) statistical software.
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Cancer September 15, 2017 Sensitivity Analysis Sensitivity analysis using 1-to-1 propensity score matching was performed to ensure patients who received CCRT were equivalent to those who received RT alone with regard to all covariates. Groups were matched based on age, sex, race, Hispanic ethnicity, insurance type, median income, educational level, US Census region of residence, population density of region of residence, distance from residence to treatment facility, year of diagnosis, T classification, N classification, CDCS, extent of TURBT, and total RT dose received. A multivariable logistic regression procedure was used to calculate and output the predicted probability, or the propensity score, for each group. Using a greedy algorithm, case and control records then were matched 1:1 based on their derived propensity scores. The algorithm makes "best" matches first and "next-best" matches next, in a hierarchical sequence. Best matches are those with the highest digit match on the patients' calculated propensity scores, with first cases matching on 8 digits. Conditional generalized linear mixed effects regression models then were used to confirm group equivalence. Using the matched cases, significance was determined using a univariable Cox regression frailty model that allowed for clustering of patients within their propensity score strata and treatment facility type. 19 
RESULTS
Patient Cohort Characteristics
A total of 1369 elderly patients with cT2-4, N0-3, M0 transitional cell MIBC who were treated with external beam RT from 2004 to 2013 met eligibility criteria; 739 patients (54%) received RT alone and 630 (46%) received CCRT. Clinical and demographic characteristics are provided in Table 1 . Comparing patients who received CCRT with those who received RT alone, there was a statistically significant difference in age noted when explored as a continuous variable (P<.0001).
Univariable Analysis
UVA for OS is described in Table 2 . For the entire cohort, the 2-year OS rate was 48%. When stratifying by the use of CCRT, the 2-year OS rate was 56% and 42%, respectively, for those treated with and without CCRT (P<.001). The Kaplan-Meier OS curve is shown in Figure 
Multivariable Analysis
MVA results for the entire study cohort using a multivariable Cox regression frailty model are shown in Table 3 . After matching for all the covariates listed in Table 1 , the statistically significant difference in OS among patients treated with CCRT versus those treated with RT alone was preserved. There were 485 records in each group, for a total of 970 matched cases. The instantaneous hazard of death for elderly patients who received CCRT was 23% lower when compared with those who received RT alone (HR, 0.77; 95% CI, 0.67-0.90 [P<.001]).
DISCUSSION
We used the NCDB to estimate the OS benefit of CCRT compared with RT alone in the treatment of elderly patients with MIBC. When interpreting MVA and 1-to-1 propensity score-matched sensitivity analysis, there was a statistically significant association noted between improved OS and CCRT. Overall, the instantaneous hazard of death for patients treated with CCRT was reduced by approximately 23% to 26% compared with those receiving RT alone. To date, there have been 2 multicenter, phase 3, prospective randomized trials comparing CCRT with RT alone for the treatment of patients with MIBC. 10, 11 Coppin et al randomized 99 patients who were diagnosed with MIBC to receive RT alone or preoperative RT with or without concurrent cisplatin; however, the maximum eligibility age was 76 years. 11 Similarly, James et al randomized 360 patients with MIBC to RT with or without concurrent chemotherapy. 11 For this trial, the interquartile range for patient age was 64.1 to 76.2 years. Because patients aged 80 years comprise a small percentage of those enrolled in CCRT trials, the incremental benefit of CCRT in elderly patients remains unclear, thereby questioning the applicability of the results of these randomized trials to the elderly population.
Unfortunately, elderly patients with MIBC tend to receive less curative treatment. Approximately 23% to 35% of patients aged 70 to 80 years do not receive curative therapy, and this increases to approximately 35% to 55% of patients for those aged >80 years. [13] [14] [15] [16] Gray et al reported that younger patients were much more likely to receive curative treatment, defined as radical or partial cystectomy or definitive RT/chemoradiotherapy. Specifically, of patients aged 81 to 90 years, 35% were treated with curative intent, and <15% of those aged >90 years received curative treatment. 15 In the patient cohort in the current study, before excluding patients based on the RT dose received, approximately 51% of elderly patients with locoregional disease did not receive curative treatment, defined as an RT dose 60 Gy with or without concurrent chemotherapy. This again calls attention to this undertreated population, and further raises the question of whether elderly patients in the United States would derive the same benefit from the addition of concurrent chemotherapy to RT as younger patients. When comparing the reduction in mortality secondary to the addition of concurrent chemotherapy, Coppin et al reported a 25% reduction (HR, 0.75; 95% CI, 0.50-1.12); James et al reported an 18% reduction (HR, 0.82; 95% CI, 0.63-1.09 [P 5 .16]); and in the current study of elderly patients, we reported a 23% reduction (HR, 0.77; 95% CI, 0.66-0.89 [P<.001]). 10, 11 Compared with the randomized trials, the data from the elderly patients in the current study demonstrate a similar survival benefit with the use of CCRT.
The use of TMT in elderly patients with MIBC has been studied previously. Turgeon and Souhami 20 conducted a review of the use of TMT for MIBC in elderly patients, in which they presented a table of outcomes and toxicity data from 8 publications and 4 conference abstracts, summing to a total of 496 elderly patients. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Although the definition of "elderly" is variable in the literature, Turgeon and Souhami reported the most common definition of elderly to be those aged 70 years, which was used in greater than one-half of the studies reviewed. The median reported age of patients in the reviewed studies was 78 years. The oldest definition of elderly used was age 78 years. 31 In this study, the definition of elderly was pushed further back to age 80 years, primarily to identify a subset of patients for whom randomized data do not exist. In the elderly patient population in the current study, there remained a clear OS benefit for the use of CCRT for the treatment of MIBC.
Although many elderly patients have comorbid disease and a reduced performance status that limit their therapeutic options, age alone should not prevent patients from receiving potentially curative treatment. Thus, the current study is significant because it demonstrates an association between OS and CCRT in the elderly patient population with MIBC, suggesting that CCRT should be considered in these individuals. As shown on MVA and with propensity score matching, this OS benefit appears to be independent of CDCS, patient age, and tumor characteristics. Our use of propensity score matching helped to limit the impact of selection bias due to confounders on the current study results.
Although the current study is subject to the inherent limitations of a retrospective study, it can inform clinical practice because there are limited data regarding the use of CCRT in elderly patients with MIBC, particularly those aged 80 years. Data regarding toxicity, local control, quality of life, and cancer-specific survival are not available in the NCDB. Without these data, it is difficult to ascertain the role of competing morbidities on survival, and thus the impact of competing morbidities on the results of the current study. The lack of data regarding performance status in the NCDB is limited further by its sole use of the CDCS because it is reported with only 3 possibilities. In other words, all patients who receive a CDCS of >2 still are reported as having a CDCS of 2 despite significant variations in performance status for patients with a CDCS of >2. The quality of the CDCS data also may cause controversy because each score is dependent on the methodology of the centers in determining the score. Without these risk factors being properly accounted for on MVA and the propensity score matching, the significance of the results is weakened. Selection bias may complicate the interpretation of the results of the current study, but the propensity score matching helped to minimize this bias. Only cases treated at CoC-accredited programs are recorded in the NCDB, and thus the findings may not be reflective of cases from non-CoC-accredited programs. However, it is unclear why the results from CoC-accredited programs cannot be generalized to non-CoC-accredited programs. Finally, the median follow-up of the current study was relatively short and therefore conclusions regarding longer-term differences among the groups could not be made.
Conclusions
The results of the current study demonstrate that CCRT is associated with improved OS compared with the use of RT alone in elderly patients with MIBC. Although a randomized trial in this specific population would be the optimal approach for establishing causality, this is unlikely to be conducted, and thus the results of the current Original Article
